A new dawn breaks for blood tests in neurological diseases, though future data remain important.
Evaluate Vantage | June 2, 2023
Qalsody, Biogen’s therapy for a specific form of amyotrophic lateral sclerosis, in April became the first neurological drug whose accelerated approval was based on a levels of a surrogate biomarker in patients’ blood. This is great news for Quanterix, maker of the leading blood test for the biomarker in question, neurofilament light chain.
“Blood is a great proxy for whether the drug is working the way you’d like it to work,” says Masoud Toloue, chief executive of Quanterix. The group hopes that Qalsody’s approval will presage the use of more blood biomarkers for approval decisions and other applications. But some clinical data have been questionable, and much will depend on Qalsody’s confirmatory trial.
Related Posts
Spatial Analysis
Snapshots of Health Innovation From the Edison Awards
Building the Tools Parkinson’s Disease Research Needs
A Q&A with Kishore Malyavantham, PhD, VP of R&D at Quanterix and Co-Investigator, PD-BUILD Quanterix has been named a Co-Investigator institution in PD-BUILD (Biomarker Utilization, Innovation, and Laboratory-to-Deployment), a new project…
Quanterix Named to ASAP CRN 2026 PD-BUILD Program with MJFF Support
Part of a global effort to advance Parkinson’s disease biomarkers through standardized, scalable assay development Quanterix has been selected as a Co-Investigator institution in the PD-BUILD program, part of the…
Neurology
Why biomarkers are no longer supplemental
Quanterix makes the case with ctDNA in oncology, p-tau217 in Alzheimer’s and a lab model built for longitudinal, regulatory-grade data. Biomarkers have moved from “nice-to-have” to the backbone of drug…
Neurology
Preparing The Market for Blood-Based Biomarkers
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, outlined strategies for integrating blood-based biomarkers into routine clinical care pathways, ensuring minimal disruption for patients and clinicians. Watch the full…
Neurology
Challenges of Positioning an Ultra-Sensitive Platform
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed challenges in positioning Simoa in the precision health market, stressing its accuracy and reliability in diverse populations. Watch the full…
Neurology
Translating Complex Scientific Findings into Actionable Insights
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed translating complex scientific findings into actionable insights for healthcare providers and stakeholders, emphasizing the importance of early disease detection. Watch…
Neurology
AI and the rise of blood-based biomarkers heralds new era for neurological diagnostics
Advances in blood-based biomarkers are transforming early and accurate Alzheimer’s disease detection, offering less invasive, cost-effective alternatives to traditional diagnostic methods. Quanterix, a company working at the very frontiers of…